Provider of support for innovation funding applications

The company provides a specialised service that enables its clients to maximise innovation funding from various Government schemes, including R&D tax relief, R&D allowances, grants, patent box tax relief, and land remediation tax relief.

With extensive sector knowledge and experience, particularly in healthcare technology and construction, the company is able to provide a more in-depth understanding of the specific requirements of these industries, helping its clients to identify and unlock the financial benefits inherent in their operations.

At present, the company caters to over 250 clients, including several blue-chip organisations, benefiting from a 95% retention rate and client relationships spanning over six years.

The business is being offered for sale to facilitate its expansion under new ownership.

Offers invited.

Key Highlights

– An award-winning company with an excellent industry reputation for the quality and professionalism of its services and the added value brought by its knowledgeable team.

– Has submitted over 800 individual R&D tax claims during its time in operation, none of which have been retracted following a challenge from HMRC, as well as successfully defending many claims even up to first-tier tribunal.

– Clients include several well-known organisations run by respected industry professionals, with the calibre of the company’s portfolio increasing the credibility and eligibility of the claims it submits.

– Shareholders are willing to remain with the business post-sale, allowing a new owner to benefit from their significant expertise of a range of sectors and facilitate the growth of the company.

– Operates from leasehold premises in Central London, with scope to be relocated to any location, should a client prefer.

Financial Highlights

– Turnover of £1.2m for YE23, with an adjusted EBITDA of £665k.

– Turnover of £1.1m for YE24, with an adjusted EBITDA of £530k.

– Projected turnover of £1.35m for YE25, with an adjusted EBITDA of £815k.

– Pipeline of confirmed and ongoing work (already signed) expected to generate £1.35m in revenue (£455k of R&D already delivered as of July 24, £59k of grants already delivered, £220k planned for grants, and the remainder planned for R&D). This could be increased further with several opportunities that are currently under negotiation with clients in the sports science, waste management and healthcare sectors, amongst others.

– Considerable scope to increase turnover through the exploration of cross-selling opportunities, one of which could generate up to £1m in additional revenue.